Oruka Therapeutics (ORKA) Cash & Equivalents (2010 - 2026)

Oruka Therapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $491.8 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 488.53% year-over-year to $491.8 million in Q1 2026; TTM through Mar 2026 was $491.8 million, a 488.53% increase from a year earlier, with the FY2025 full-year figure at $44.8 million, down 27.32% from the prior year.
• Cash & Equivalents rose to $491.8 million in Q1 2026 per ORKA's latest filing, from $44.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $498.7 million in Q3 2025 and bottomed at $33.3 million in Q2 2024.
• The 5-year median for Cash & Equivalents is $44.8 million (2025), against an average of $121.0 million.
• Across the five-year window, Cash & Equivalents jumped 947.94% in 2024 and slipped 27.32% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $42.4 million in 2022, then dropped by 11.81% to $37.4 million in 2023, then surged by 64.5% to $61.6 million in 2024, then dropped by 27.32% to $44.8 million in 2025, then surged by 999.07% to $491.8 million in 2026.
• Per Business Quant, the three latest ORKA Cash & Equivalents figures stand at $491.8 million (Q1 2026), $44.8 million (Q4 2025), and $498.7 million (Q3 2025).